Post by Tsung Tan
Programmable & Targeted Drug Delivery | Delivering Above & Beyond | Approaches to Achieve Extended PK Profiles in Drug Discovery | Making a Real Difference
Re-sharing Drug Delivery Article as still very relevant for new comers and those looking beyond what is typically done. As updates, here are some highlights - new publications in Nature, Science, Cancer Discovery where Recovery Mode (saline to drug), refilling and programmability used as required. Kleeman, S. O., Michalski, K., Zhao, X., Steigerwald, R., Ferrer, M., Levett, L., ... & Janowitz, T. (2026). Ectopic NMDAR expression in cancer unmasks germline-encoded autoimmunity. Nature, 1-13. (>45K article views, 1 citation (first publication 19 May 2026). https://lnkd.in/gzQMkUr3 Weiss, A., Lorthiois, E., Barys, L., Beyer, K. S., Bomio-Confaglia, C., Burks, H., ... & Brachmann, S. M. (2022). Discovery, preclinical characterization, and early clinical activity of JDQ443, a structurally novel, potent, and selective covalent oral inhibitor of KRASG12C. Cancer Discovery, 12(6), 1500-1517. (> Total Views 21,292, 113 to 125 citations) https://lnkd.in/d8WnjtCj Manfredi-Lozano, M., Leysen, V., Adamo, M., Paiva, I., Rovera, R., Pignat, J. M., ... & Prevot, V. (2022). GnRH replacement rescues cognition in Down syndrome. Science, 377(6610), eabq4515. (>22,524 downloads, 100 citations) https://lnkd.in/eB2s6upW
